Karyopharm Therapeutics (NASDAQ:KPTI) and Merck & Co., Inc. (NYSE:MRK) Head to Head Review

Merck & Co., Inc. (NYSE:MRK) and Karyopharm Therapeutics (NASDAQ:KPTI) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and target prices for Merck & Co., Inc. and Karyopharm Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0	10	17	0	2.63
Karyopharm Therapeutics	1	2	3	1	2.57

Merck & Co., Inc. presently has a consensus price target of $151.92, indicating a potential upside of 5.81%. Karyopharm Therapeutics has a consensus price target of $11.50, indicating a potential upside of 3,223.70%. Given Karyopharm Therapeutics’ higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Merck & Co., Inc..

Valuation & Earnings

This table compares Merck & Co., Inc. and Karyopharm Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01 billion	5.45	$18.25 billion	$1.25	114.86
Karyopharm Therapeutics	$146.07 million	0.05	-$196.04 million	($13.09)	-0.03

Merck & Co., Inc. has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Merck & Co., Inc. has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Karyopharm Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Summary

Merck & Co., Inc. beats Karyopharm Therapeutics on 11 of the 15 factors compared between the two stocks.

About Merck & Co., Inc.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.